Recherchemedicale.com
Mélanges complexes
Produits biologiques
Vaccins
Vaccins antiviraux
Vaccins contre le SIDA
Vaccins contre le SIDA : Questions médicales fréquentes
Diagnostic
2
Vaccins
SIDA
Essais cliniques
VIH
Tests de dépistage
Diagnostic
Symptômes
2
SIDA
Symptômes
Infections opportunistes
Vaccins
Effets secondaires
SIDA
Traitements
2
Traitements antirétroviraux
Vaccins
SIDA
VIH
Antirétroviraux
Traitements
Complications
2
Complications
SIDA
Infections opportunistes
Vaccins
Complications
Réactions allergiques
Facteurs de risque
2
Facteurs de risque
VIH
Comportements à risque
Vaccins
Prévention
Facteurs de risque
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vaccins contre le SIDA : Questions médicales les plus fréquentes",
"headline": "Vaccins contre le SIDA : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vaccins contre le SIDA : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-01",
"dateModified": "2024-12-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vaccins contre le SIDA"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Vaccins antiviraux",
"url": "https://recherchemedicale.com/mesh/D014765",
"about": {
"@type": "MedicalCondition",
"name": "Vaccins antiviraux",
"code": {
"@type": "MedicalCode",
"code": "D014765",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D20.215.894.899"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vaccins contre le SIDA",
"alternateName": "AIDS Vaccines",
"code": {
"@type": "MedicalCode",
"code": "D016915",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Jianzhou Yang",
"url": "https://recherchemedicale.com/author/Jianzhou%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Preventive Medicine, Changzhi Medical College, Changzhi, China."
}
},
{
"@type": "Person",
"name": "Xiangjun Zhang",
"url": "https://recherchemedicale.com/author/Xiangjun%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Public Health, University of Tennessee, Knoxville, TN, United States."
}
},
{
"@type": "Person",
"name": "Xiaojie Huang",
"url": "https://recherchemedicale.com/author/Xiaojie%20Huang",
"affiliation": {
"@type": "Organization",
"name": "Beijing Youan Hospital, Capital Medical University, Beijing, China."
}
},
{
"@type": "Person",
"name": "Maohe Yu",
"url": "https://recherchemedicale.com/author/Maohe%20Yu",
"affiliation": {
"@type": "Organization",
"name": "Tianjin Centers for Disease Control and Prevention, Tianjin, China."
}
},
{
"@type": "Person",
"name": "Guanghua Lan",
"url": "https://recherchemedicale.com/author/Guanghua%20Lan",
"affiliation": {
"@type": "Organization",
"name": "Guangxi Center for Disease Prevention and Control, Nanning, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The Failure of AIDS Vaccine Efficacy Trials: Where to Go from Here.",
"datePublished": "2023-03-14",
"url": "https://recherchemedicale.com/article/36916947",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1128/jvi.00211-23"
}
},
{
"@type": "ScholarlyArticle",
"name": "Overcoming Vaccine Hesitancy for Future COVID-19 and HIV Vaccines: Lessons from Measles and HPV Vaccines.",
"datePublished": "2022-09-17",
"url": "https://recherchemedicale.com/article/36114951",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11904-022-00622-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Computational design of vaccine immunogens.",
"datePublished": "2022-10-21",
"url": "https://recherchemedicale.com/article/36279815",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.copbio.2022.102821"
}
},
{
"@type": "ScholarlyArticle",
"name": "Triggering rare HIV antibodies by vaccination.",
"datePublished": "2022-12-01",
"url": "https://recherchemedicale.com/article/36454831",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1126/science.adf3722"
}
},
{
"@type": "ScholarlyArticle",
"name": "HIV-1 therapeutic vaccines in clinical development to intensify or replace antiretroviral therapy: the promising results of the Tat vaccine.",
"datePublished": "2022-06-17",
"url": "https://recherchemedicale.com/article/35695268",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/14760584.2022.2089119"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Recherchemedicale.com",
"item": "https://recherchemedicale.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Mélanges complexes",
"item": "https://recherchemedicale.com/mesh/D045424"
},
{
"@type": "ListItem",
"position": 3,
"name": "Produits biologiques",
"item": "https://recherchemedicale.com/mesh/D001688"
},
{
"@type": "ListItem",
"position": 4,
"name": "Vaccins",
"item": "https://recherchemedicale.com/mesh/D014612"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vaccins antiviraux",
"item": "https://recherchemedicale.com/mesh/D014765"
},
{
"@type": "ListItem",
"position": 6,
"name": "Vaccins contre le SIDA",
"item": "https://recherchemedicale.com/mesh/D016915"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vaccins contre le SIDA - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vaccins contre le SIDA",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-01-22",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vaccins contre le SIDA",
"description": "Comment évaluer l'efficacité d'un vaccin contre le SIDA ?\nQuels tests sont utilisés pour diagnostiquer le VIH ?",
"url": "https://recherchemedicale.com/mesh/D016915#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vaccins contre le SIDA",
"description": "Quels sont les symptômes du VIH/SIDA ?\nLe vaccin peut-il provoquer des symptômes ?",
"url": "https://recherchemedicale.com/mesh/D016915#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vaccins contre le SIDA",
"description": "Comment les vaccins contribuent-ils à la prévention du SIDA ?\nQuelles autres méthodes préviennent le VIH ?",
"url": "https://recherchemedicale.com/mesh/D016915#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vaccins contre le SIDA",
"description": "Les vaccins remplacent-ils les traitements antirétroviraux ?\nQuels traitements sont disponibles pour le VIH ?",
"url": "https://recherchemedicale.com/mesh/D016915#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vaccins contre le SIDA",
"description": "Quelles complications peuvent survenir sans vaccin ?\nLes vaccins peuvent-ils causer des complications ?",
"url": "https://recherchemedicale.com/mesh/D016915#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vaccins contre le SIDA",
"description": "Quels sont les facteurs de risque pour le VIH ?\nLes vaccins réduisent-ils les facteurs de risque ?",
"url": "https://recherchemedicale.com/mesh/D016915#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un vaccin contre le SIDA ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par des essais cliniques mesurant la réduction des infections."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour diagnostiquer le VIH ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests sérologiques et les tests d'acide nucléique détectent le VIH dans le sang."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes du VIH/SIDA ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent fièvre, fatigue, éruptions cutanées et infections opportunistes."
}
},
{
"@type": "Question",
"name": "Le vaccin peut-il provoquer des symptômes ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires légers comme douleur au site d'injection peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment les vaccins contribuent-ils à la prévention du SIDA ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils stimulent le système immunitaire pour prévenir l'infection par le VIH."
}
},
{
"@type": "Question",
"name": "Quelles autres méthodes préviennent le VIH ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation de préservatifs et la prophylaxie pré-exposition (PrEP) sont efficaces."
}
},
{
"@type": "Question",
"name": "Les vaccins remplacent-ils les traitements antirétroviraux ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les vaccins complètent les traitements, mais ne les remplacent pas."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour le VIH ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent les antirétroviraux qui contrôlent la charge virale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir sans vaccin ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Sans vaccin, le risque d'infections opportunistes et de maladies graves augmente."
}
},
{
"@type": "Question",
"name": "Les vaccins peuvent-ils causer des complications ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications graves sont rares, mais des réactions allergiques peuvent survenir."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour le VIH ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les rapports non protégés, le partage de seringues et les antécédents d'infections sont des risques."
}
},
{
"@type": "Question",
"name": "Les vaccins réduisent-ils les facteurs de risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en prévenant l'infection, les vaccins diminuent les comportements à risque associés."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 27/12/2024
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Department of Preventive Medicine, Changzhi Medical College, Changzhi, China.
Publications dans "Vaccins contre le SIDA" :
3 publications dans cette catégorie
Affiliations :
Department of Public Health, University of Tennessee, Knoxville, TN, United States.
Publications dans "Vaccins contre le SIDA" :
3 publications dans cette catégorie
Affiliations :
Beijing Youan Hospital, Capital Medical University, Beijing, China.
Publications dans "Vaccins contre le SIDA" :
3 publications dans cette catégorie
Affiliations :
Tianjin Centers for Disease Control and Prevention, Tianjin, China.
Publications dans "Vaccins contre le SIDA" :
3 publications dans cette catégorie
Affiliations :
Guangxi Center for Disease Prevention and Control, Nanning, China.
Publications dans "Vaccins contre le SIDA" :
3 publications dans cette catégorie
Affiliations :
The Second Hospital of Huhhot, Huhhot, China.
Publications dans "Vaccins contre le SIDA" :
3 publications dans cette catégorie
Affiliations :
Clinical Research Academy, Peking University Shenzhen Hospital, Peking University, Shenzhen, China.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Netherlands Organization for Applied Scientific Research (TNO), Expertise Group Child Health, Leiden, Netherlands.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Physical Sciences and Engineering Division, Kaust Catalysis Center, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok, Thailand.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok, Thailand.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Department of Research and Innovation, STEMskills Research and Education Lab Private Limited, Faridabad, Haryana, India.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Physical Sciences and Engineering Division, Kaust Catalysis Center, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. Electronic address: schakr11@jhu.edu.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Department of Epidemiology and Biostatistics, School of Public Health, Jilin University, Changchun, China.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Department of Emergency Medicine, Shenzhen Hospital, Peking University, Shenzhen, China.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
Changchun Maternity Hospital, Changchun, China.
Publications dans "Vaccins contre le SIDA" :
2 publications dans cette catégorie
Affiliations :
The Department of Nursing, School of Health Sciences, Ariel University, Ariel 40700, Israel.
Publications dans "Vaccins contre le SIDA" :
The seven AIDS vaccine efficacy trials have yielded extremely disappointing results at great expense. Greater stringency is needed for government support of AIDS vaccine efficacy trials....
The discovery of vaccines significantly reduced morbidity and mortality of infectious diseases and led to the elimination and eradication of some. Development of safe and effective vaccines is a criti...
We conducted a narrative review of studies on interventions to address measles and human papillomavirus vaccine hesitancy. We discussed how lessons learned from these studies could be applied towards ...
We found that there are several successful approaches to improving vaccine acceptance. Interventions should be context specific and build on the challenges highlighted in various settings....
Strategies could be used alone or in combination with others. The most successful interventions directly targeted the population for vaccination. Use of financial incentives could be a potential tool ...
Computational protein engineering has enabled the rational design of customized proteins, which has propelled both sequence-based and structure-based immunogen engineering and delivery. By discerning ...
Clinical trial shows that an HIV vaccine can elicit rare antibodies, but there is more to do....
Upon the introduction of the combination antiretroviral therapy (cART), HIV infection has become a chronic disease. However, cART is unable to eradicate the virus and fails to restore the CD4 counts i...
Here, we briefly discuss the obstacles to the development and evaluation of the efficacy of therapeutic vaccines and review recent approaches evaluated in clinical trials....
Although vaccines were generally safe and immunogenic, evidence of efficacy was negligible or marginal in most trials. A notable exception is the therapeutic Tat vaccine approach showing promising res...
Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Our objective was to compare COVID-19 vaccine immunogenicity in PWH to HIV-negative...
In a Canadian multi-center prospective, observational cohort of PWH receiving at least two COVID-19 vaccinations, we measured vaccine-induced immunity at 3 and 6 months post 2nd and 1-month post 3rd d...
The primary outcome was the percentage of PWH mounting vaccine-induced immunity [co-positivity for anti-IgG against SARS-CoV2 Spike(S) and receptor-binding domain proteins] 6 months post 2nd dose. Uni...
Data from 294 PWH and 267 controls were analyzed. Immunogenicity was achieved in over 90% at each time point in both groups. The proportions of participants achieving comparable anti-receptor-binding ...
Vaccine-induced IgG was elicited in the vast majority of PWH and was overall similar between groups. A slightly lower proportion of PWH vs. controls maintained vaccine-induced anti-S IgG immunity 6 mo...
The identification of baseline host determinants that associate with robust HIV-1 vaccine-induced immune responses could aid HIV-1 vaccine development. We aimed to assess both the collective and relat...
This was a meta-analysis of individual participant data, with studies chosen based on participant-level (vs. study-level summary) data availability within the HIV-1 Vaccine Trials Network. We assessed...
Overall, 30.1%, 50.5%, 36.2%, and 13.9% of participants were categorized as High responders for gp120 IgG, gp140 IgG, gp41 IgG, and Env-specific CD4+ T-cell vaccine-induced responses, respectively. Wh...
The identified features should be studied further in pursuit of intervention strategies to improve vaccine responses and may be adjusted for in analyses of immune response data to enhance statistical ...
National Institute of Allergy and Infectious Diseases (UM1AI068635 to YH, UM1AI068614 to GDT, UM1AI068618 to MJM, and UM1 AI069511 to MCK), the Duke CFAR P30 AI064518 to GDT, and National Institute of...
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has precipitated a global health crisis of unprecedented proportions. Due to its severe...
HIV vaccine development has been hindered by significant challenges over four decades. Despite persistent efforts, all efficacy trials to date have yielded disappointing results. This has pushed the f...
The development of an effective vaccine against HIV is desperately needed. The successive failures of HIV vaccine efficacy trials in recent decades have shown the difficulty of inducing an appropriate...